ScPharmaceuticals : September 2021 Corporate Presentation

H.C.Wainwright 23rd

Annual Global Investment

Conference

September 13 - 15, 2021

Disclaimer

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our launch and commercialization plans, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding business strategy, product approval, current and prospective collaborations, timing and likelihood of success, expectations regarding market acceptance and size, plans for launch and commercialization, plans and objectives of management for future operations, the company's financial position and future results of anticipated product candidates, are forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the FDA's review requirements, the planned resubmission of the FUROSCIX NDA, including potential timing of the resubmission, the ability of the FUROSCIX Infusor to appropriately deliver therapy, the receipt of regulatory approval for FUROSCIX Infusor or any of our other product candidates or, if approved, the successful commercialization of such products, including market acceptance and expected payer cost savings, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, and the risk that the current COVID-19 pandemic will impact the Company's planned Phase 4 study of FUROSCIX, and other operations and the Company's projected financial guidance. For a discussion of other risks and uncertainties, and other important factors, see the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as other risks detailed in the Company's subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Investment Highlights

Advancing patient care and reducing healthcare costs through innovative subcutaneous delivery

• Two late-stage programs addressing multi billion-dollar markets
• • FUROSCIX® for Heart Failure (HF)
  • • A $5.9B total US market opportunity
  • scCeftriaxone, a potentially novel delivery of a broad-spectrum antibiotic
  • • A $4.5B total US market opportunity
• Clear value proposition and established reimbursement model for FUROSCIX
• Well defined development plan leveraging FDA's 505(b)(2) pathway
• Strong intellectual property coverage for FUROSCIX through 2034
• Strong financial position with cash, cash equivalents, restricted cash and investments of $90.2 million as of June 30, 2021

3

Senior Management and Board of Directors

John H. Tucker

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Michael Hassman

SENIOR VICE PRESIDENT, OPERATIONS

John Mohr, Pharm. D.

SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Rachael Nokes

SENIOR VICE PRESIDENT, FINANCE

Board of Directors

William Abraham, MD	Jack Khattar
Professor of Internal Medicine	CEO, Supernus Pharmaceuticals
(Cardiology), Ohio State	Leonard Schaeffer
University
	Founding Chairman & CEO,
Mette Kristine Agger	WellPoint
Lundbeckfond Ventures	Klaus Veitinger, MD, PhD
Minnie Baylor-Henry	OrbiMed Advisors
B-Henry & Associates, J&J	John H. Tucker
Sara Bonstein	CEO, scPharmaceuticals
CFO Insmed Incorporated
Fred Hudson
Former partner, KPMG

4

Large Unmet Need in Heart Failure (HF)

Lead program targets HF - a large global market opportunity with a clear value proposition

• Prevalence of HF is 7.2 million adults in the US1 and 15.8 million adults in the G71
• In the US 4.0 million HF events occur annually1,2,3
• • Congestion is the most common cause of hospitalization4
• $5.9B accessible market opportunity in the US
• HF patients represent 33% ($123B) of annual Medicare Part A and B spending5
• Potential for significant cost savings for payers and hospitals by reducing patient hospital admission/readmission rates

1. Decision Resource Group Report 2020 HF Disease Landscape & Forecast, Table 6 pg 52: forecast of ~3.3M diagnosed events of Acute HF in the US for 2022 and HF prevalence of 7.2M cases note: G7=US, Germany, France, UK, Italy, Spain, Japan

equals 15.8M cases .2. Virani, et. al. Circulation 2020;:e374 HF clinic visits. 3. Data on file. scPharmaceuticals, Burlington, MA. 4. Mullens W, et al. Eur J Heart Fail 2019; 21(2):137-155. 5. Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017. http://us.milliman.com/insight/2017/The-cost-burden-of-worsening-heart-failure-in-the-Medicare-fee-for-service-population-An-actuarial-analysis/

5